0

Liver Cancer Drugs Market by Type and Geography - Forecast and Analysis 2022-2026

  • Published: Mar 2022
  • Pages: 120
  • SKU: IRTNTR72448
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single User:

    Quick and easy buy and download option

  • Enterprise:

    Flexible option - Complimentary customization included

2500 USD

The liver cancer drugs market share is expected to increase by USD 5.29 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 14.67%. This liver cancer drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers liver cancer drugs market segmentation by:

  • Type - Immunotherapy and targeted therapy
  • Geography - North America, Europe, Asia, and Rest of World (ROW)

What will the Liver Cancer Drugs Market Size be During the Forecast Period?

Liver Cancer Drugs Market Size

Download the Free Report Sample to Unlock the Liver Cancer Drugs Market Size for the Forecast Period and Other Important Statistics

 

The liver cancer drugs market report also offers information on several market vendors, including Alnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Q BioMed Inc. among others.

Liver Cancer Drugs Market: Key Drivers, Trends, and Challenges

The increasing incidence of liver cancer is notably driving the growth, although factors such as only curative option is surgical resection and transplantation may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the liver cancer drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Liver Cancer Drugs Market Driver

One of the key factors driving growth in the liver cancer drugs market is the increasing incidence of liver cancer. Liver cancer is among the leading causes of cancer-related deaths globally. The increase in the incidence of risk factors like hepatitis B and C and underlying cirrhosis will lead to the rise in the risk of liver cancer depends on the etiology. In the US, among patients with certain liver cancers in US, hepatitis C is present in more than half of this population. Around 15% of this group have hepatitis B. Every year, in the US, about 31,000 people get liver cancer.  In the US, fatty liver is attributed as a major cause of liver cancer, which is followed by hepatitis C. Long-term alcohol consumption is also the primary reason for the increase in the incidence of liver cancer. Furthermore, the increase in the incidence of new risk factors like diabetes, obesity, and related non-alcoholic fatty liver disease may also be associated with the increase in the incidence of liver cancer.

Key Liver Cancer Drugs Market Trend

The use of mABs is a liver cancer drugs market trend that is expected to have a positive impact in the coming years. Mostly, liver cancer does not respond to chemotherapy, and monoclonal antibody therapies represent a new promising approach to treat liver cancer. The main challenge is the lack of understanding about tumor-specific targets. Research is being conducted to develop high-stability and high-affinity antibodies and fragments, which can target tumor-specific antigens in liver cancer. The main advantages of monoclonal antibodies are their sensitivity and their ability to create a level of specificity, which reduces the chances of deleterious side effects. Another advantage of using monoclonal antibodies for liver cancer is that they are highly stable. Currently, only one monoclonal antibody is approved to treat liver cancer. However, the pipeline has multiple monoclonal antibodies at different stages of evaluation.

Key Liver Cancer Drugs Market Challenge

The only curative option being surgical resection and transplantation will be a major challenge for the liver cancer drugs market during the forecast period. The treatment of liver cancer is decided by the stage of the disease and liver functioning. Disease-modifying drugs are neither available in the market nor in the pipeline to potentially cure liver cancer. Globally, consensus on the surgical treatment of liver cancer being a recommended option is yet to be obtained, which can be attributed to the variations in healthcare systems in different regions.  Liver resection can be performed only in candidates who meet prerequisites for surgery. However, surgery is often associated with a high recurrence rate of tumors. Patients with recurrent tumors are evaluated for liver transplantation.

This liver cancer drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global liver cancer drugs market as a part of the global pharmaceuticals market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the liver cancer drugs market during the forecast period.

Who are the Major Liver Cancer Drugs Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • Alnylam Pharmaceuticals Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • Eureka Therapeutics
  • Exelixis Inc.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Lion TCR Pte. Ltd
  • Merck and Co. Inc.
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Q BioMed Inc.

 

This statistical study of the liver cancer drugs market encompasses successful business strategies deployed by the key vendors. The liver cancer drugs market is fragmented and the vendors are deploying growth strategies such as acquiring and forming mergers with other vendors to expand their portfolio of offerings and increase their market share to compete in the market.

Product Insights and News

  • Bayer AG - The company offers drugs, treatment and diagnoses for liver cancer.

  • AstraZeneca Plc - The company offers  Orphan Drug Designation (ODD) for the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer.

In order to make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The liver cancer drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Liver Cancer Drugs Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the liver cancer drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Liver Cancer Drugs Market?

Liver Cancer Drugs Market Market segmentation by region

For more insights on the market share of various regions Request for a FREE sample now!

42% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for liver cancer drugs in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.

The development and launch of treatment therapies for liver cancer will facilitate the liver cancer drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 pandemic negatively impacted the region in 2020. Governments of the countries in the region imposed a nationwide lockdown, which limited the movement of people. In the first half of 2021, with the gradual decrease in the number of COVID-19 cases, lockdowns were lifted, leading to the reopening of healthcare facilities and clinics. Regular operations and checkups have also started up for cancer. This, in turn, will have a positive impact on the regional liver cancer drugs market and thus, we can see a high growth rate during the forecast period.

What are the Revenue-generating Type Segments in the Liver Cancer Drugs Market?

Liver Cancer Drugs Market Segmentation

To gain further insights on the market contribution of various segments Request for a FREE sample

The liver cancer drugs market share growth by the immunotherapy segment will be significant during the forecast period. The market is expected to experience moderate growth during the forecast period. Immunotherapy is a specific treatment that uses the immune system of the body to fight cancer.

This report provides an accurate prediction of the contribution of all the segments to the growth of the liver cancer drugs market size and actionable market insights on post COVID-19 impact on each segment.

 

Liver Cancer Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 14.67%

Market growth 2022-2026

$ 5.29 billion

Market structure

Fragmented

YoY growth (%)

10.4

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 42%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Alnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Q BioMed Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Liver Cancer Drugs Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive liver cancer drugs market growth during the next five years
  • Precise estimation of the liver cancer drugs market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the liver cancer drugs industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of liver cancer drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Type

    • 5.1 Market segments
      • Exhibit 24: Chart on Type - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
    • 5.2 Comparison by Type
      • Exhibit 26: Chart on Comparison by Type
      • Exhibit 27: Data Table on Comparison by Type
    • 5.3 Immunotherapy - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Immunotherapy - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Immunotherapy - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Immunotherapy - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Immunotherapy - Year-over-year growth 2021-2026 (%)
    • 5.4 Targeted therapy - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Targeted therapy - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Targeted therapy - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Targeted therapy - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Targeted therapy - Year-over-year growth 2021-2026 (%)
    • 5.5 Market opportunity by Type
      • Exhibit 36: Market opportunity by Type ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 40: Chart on Geographic comparison
      • Exhibit 41: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Germany - Market size and forecast 2021-2026
      • Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.9 China - Market size and forecast 2021-2026
      • Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)
    • 7.10 Canada - Market size and forecast 2021-2026
      • Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.11 UK - Market size and forecast 2021-2026
      • Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 78: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 81: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 82: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 83: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 84: Matrix on vendor position and classification
            • 10.3 AstraZeneca Plc
              • Exhibit 85: AstraZeneca Plc - Overview
              • Exhibit 86: AstraZeneca Plc - Product / Service
              • Exhibit 87: AstraZeneca Plc - Key news
              • Exhibit 88: AstraZeneca Plc - Key offerings
            • 10.4 Bayer AG
              • Exhibit 89: Bayer AG - Overview
              • Exhibit 90: Bayer AG - Business segments
              • Exhibit 91: Bayer AG - Key news
              • Exhibit 92: Bayer AG - Key offerings
              • Exhibit 93: Bayer AG - Segment focus
            • 10.5 Bristol-Myers Squibb Co.
              • Exhibit 94: Bristol-Myers Squibb Co. - Overview
              • Exhibit 95: Bristol-Myers Squibb Co. - Product / Service
              • Exhibit 96: Bristol-Myers Squibb Co. - Key offerings
            • 10.6 Eisai Co. Ltd.
              • Exhibit 97: Eisai Co. Ltd. - Overview
              • Exhibit 98: Eisai Co. Ltd. - Business segments
              • Exhibit 99: Eisai Co. Ltd. - Key offerings
              • Exhibit 100: Eisai Co. Ltd. - Segment focus
            • 10.7 Eli Lilly and Co.
              • Exhibit 101: Eli Lilly and Co. - Overview
              • Exhibit 102: Eli Lilly and Co. - Business segments
              • Exhibit 103: Eli Lilly and Co. - Key offerings
              • Exhibit 104: Eli Lilly and Co. - Segment focus
            • 10.8 Eureka Therapeutics
              • Exhibit 105: Eureka Therapeutics - Overview
              • Exhibit 106: Eureka Therapeutics - Product / Service
              • Exhibit 107: Eureka Therapeutics - Key offerings
            • 10.9 Gilead Sciences Inc.
              • Exhibit 108: Gilead Sciences Inc. - Overview
              • Exhibit 109: Gilead Sciences Inc. - Business segments
              • Exhibit 110: Gilead Sciences Inc. - Key news
              • Exhibit 111: Gilead Sciences Inc. - Key offerings
              • Exhibit 112: Gilead Sciences Inc. - Segment focus
            • 10.10 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
              • Exhibit 113: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
              • Exhibit 114: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
              • Exhibit 115: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
            • 10.11 Lion TCR Pte. Ltd
              • Exhibit 116: Lion TCR Pte. Ltd - Overview
              • Exhibit 117: Lion TCR Pte. Ltd - Product / Service
              • Exhibit 118: Lion TCR Pte. Ltd - Key offerings
            • 10.12 Merck and Co. Inc.
              • Exhibit 119: Merck and Co. Inc. - Overview
              • Exhibit 120: Merck and Co. Inc. - Business segments
              • Exhibit 121: Merck and Co. Inc. - Key news
              • Exhibit 122: Merck and Co. Inc. - Key offerings
              • Exhibit 123: Merck and Co. Inc. - Segment focus

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 124: Inclusions checklist
                • Exhibit 125: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 126: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 127: Research methodology
                • Exhibit 128: Validation techniques employed for market sizing
                • Exhibit 129: Information sources
              • 11.5 List of abbreviations
                • Exhibit 130: List of abbreviations
              • The market is led by the UK, Germany, and France. The market will experience moderate growth during the forecast period. One of the major factors is the increase in the prevalence of liver cancer in the region. Liver cancer can be caused due to various infectious diseases such as chronic hepatitis B infection and hepatitis C virus infections. Liver cancer is the 18th most common cancer in the UK. In Europe, 28% of the cases of liver cancer are due to chronic hepatitis B infection, and 21% of the cases are due to hepatitis C virus infections.

                Research Framework

                Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

                TechnavioINFORMATION SOURCES

                Primary sources

                • Manufacturers and suppliers
                • Channel partners
                • Industry experts
                • Strategic decision makers

                Secondary sources

                • Industry journals and periodicals
                • Government data
                • Financial reports of key industry players
                • Historical data
                • Press releases
                Technavio

                TechnavioDATA ANALYSIS

                Data Synthesis

                • Collation of data
                • Estimation of key figures
                • Analysis of derived insights

                Data Validation

                • Triangulation with data models
                • Reference against proprietary databases
                • Corroboration with industry experts
                Technavio

                TechnavioREPORT WRITING

                Qualitative

                • Market drivers
                • Market challenges
                • Market trends
                • Five forces analysis

                Quantitative

                • Market size and forecast
                • Market segmentation
                • Geographical insights
                • Competitive landscape
                Interested in this report?
                Get your sample now!
                Liver Cancer Drugs Market market growth will increase by $5.29 bn during 2022-2026.
                The liver cancer drugs market market is expected to grow at a CAGR of 14.67% during 2022-2026.
                Technavio has segmented the liver cancer drugs market market by type (immunotherapy and targeted therapy) and geography (North America, Europe, Asia, and Rest of World (ROW)).
                Alnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Q BioMed Inc. are a few of the key vendors in the liver cancer drugs market market.
                North America will register the highest growth rate of 42% among the other regions. Therefore, the liver cancer drugs market market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
                The key factors driving the liver cancer drugs market market growth are:
                • increasing incidence of liver cancer
                • Use of mABs
                The liver cancer drugs market market vendors should focus on grabbing business opportunities from the immunotherapy segment as it accounted for the largest market share in the base year.
                • What are the key global market and the regional market share?
                • What are the revenue-generating key market segments?
                • What are the key factors driving and challenging this market’s growth?
                • Who are the key market vendors and their growth strategies?
                • What are the latest trends influencing the growth of this market?
                • What are the variables influencing the market growth in the primary regions?
                • What are the factors influencing the growth of the parent market?
                • Off-the-shelf research reports
                • Reports can be tailored to meet the customer's needs
                • Trusted by more than 100 fortune 500 organizations
                • Information about the market's key drivers, trends, and challenges
                • Parent market analysis
                • Every week, 50,000 people visit our subscription platform
                • Detailed vendors report with competitive landscape
                • Covid-19 impact and recovery analysis
                • Data on revenue-generating market segments
                • Details on the market shares of various regions
                • Five-force market analysis

                Certified ISO 9001 : 2015

                We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

                We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

                Safe and Secure SSL Encrypted
                Technavio

                info
                close
                • Single User:

                  Quick and easy buy and download option

                • Enterprise:

                  Flexible option - Complimentary customization included

                2500 USD

                Technavio Get the report (PDF) sent to your email within minutes.

                Subscribe & Save

                Get lifetime access to our
                Technavio Insights

                Customized Report as per your Business Needs

                • Our analysts will work directly with you and understand your needs
                • Get data on specified regions or segments, competitor and Vendors
                • Data will be formatted and presented as per your requirements
                • We offer $1000 worth of FREE customization at the time of purchase

                Let us help you make report more suited to your requirements.

                • Get a competitive breakdown as per your niche industry
                • Customize the data with various metrics that meet your business prerequisite
                • Understand Revenue Sources, Customers and many more
                • Details on Market Share
                • These customizations are done in a short amount of time by our analysts and industry experts
                Technavio
                Enquire Before Buying
                17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>